[Methylnaltrexone. A new approach for therapy of opioid-induced obstipation].
Chronic pain patients using opioids frequently suffer from constipation which compromises well-being. Such an opioid-induced gastro-intestinal complication can occur regularly in patients in palliative care as well as in analgesic sedated intensive care patients or during prolonged perioperative pain therapy. Discomfort and distress in the affected patients can be so severely pronounced that they would rather suffer from the pain than from the side effect of constipation. Conventional therapy can be insufficient in providing satisfactory relief of constipation, mostly because this opioid-induced bowel hypomotility can be laxative-resistant. Moreover, constipation does not decrease during the course of therapy as do other side effects. It is well known that opioid-induced constipation is mediated via activation of micro-opioid receptors in the gastrointestinal tract. Selective peripheral micro-receptor antagonists (such as methylnaltrexone, Relistor) can effectively treat opioid-induced constipation. An interference with central analgesia does not occur as the molecules cannot pass the blood-brain barrier due to their charged states. A reduction of opioid therapy or the development of withdrawal symptoms can be avoided. Studies have shown that methylnaltrexone is not only safe and efficient for chronically constipated palliative care patients but offers promising therapeutic options for further patient collectives.
Chappell
D
D
Klinik für Anaesthesiologie, Ludwig-Maximilians-Universität, Nussbaumstr. 20, 80336 München. daniel.chappell@med.uni-muenchen.de
Conzen
P
P
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003248:Constipation / Q000139:chemically induced* / Q000188:drug therapy*; D003422:Critical Care; D006801:Humans; D009271:Naltrexone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D010166:Palliative Care; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects / Q000627:therapeutic use
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D000644:Quaternary Ammonium Compounds; C032257:methylnaltrexone; D009271:Naltrexone
Br J Anaesth. 2003 Dec;91(6):815-9
14633751
Gerontol Clin (Basel). 1969;11(3):137-44
5770790
J Pain Symptom Manage. 2002 Jan;23(1):48-53
11779668
Schmerz. 2005 Jun;19(3):214-9
15004747
BMJ. 2001 May 12;322(7295):1154-8
11348910
Anesth Analg. 2004 Feb;98(2):364-370
14742371
Am J Hosp Palliat Care. 2005 Sep-Oct;22(5):375-81
16225360
JAMA. 2000 Sep 20;284(11):1383-4
10989399
J Clin Oncol. 2001 May 1;19(9):2542-54
11331334
Pain. 1999 Mar;80(1-2):215-28
10204734
Curr Opin Support Palliat Care. 2007 Aug;1(2):117-25
18685352
Support Care Cancer. 2008 May;16(5):453-9
18197439
Drugs. 2003;63(7):649-71
12656645
Support Care Cancer. 2003 Nov;11(11):679-85
14505158
J Pharmacol Exp Ther. 1990 May;253(2):784-90
2160010
N Engl J Med. 2008 May 29;358(22):2332-43
18509120
Neuropharmacology. 1999 Mar;38(3):425-32
10219980
Ann Pharmacother. 2007 Jun;41(6):984-93
17504835
Trends Neurosci. 2000 Sep;23(9):436-42
10941194
Wien Med Wochenschr. 2008;158(21-22):621-6
19052708
BMC Gastroenterol. 2006 Jun 22;6:19
16792799
Gut. 1999 Sep;45 Suppl 2:II43-7
10457044
Crit Care. 2008;12(4):161
18598388
J Support Oncol. 2009 Jan-Feb;7(1):39-46
19278178
J Clin Oncol. 1992 Jan;10(1):149-55
1345797
Nat Med. 2003 Aug;9(8):1003-8
12894165
Eur J Pain. 2009 Jan;13(1):56-64
18762438
Schmerz. 2005 Oct;19(5):447-52, 454-5
16133300
Palliat Med. 1998 Sep;12(5):375-82
9924600
J Pain Symptom Manage. 1998 Oct;16(4):240-4
9803051
Science. 2001 Jul 13;293(5528):311-5
11452128
Palliat Med. 2006 Jun;20(4):419-23
16875112
Palliat Med. 2000 Mar;14(2):111-9
10829145
Clin Pharmacol Ther. 2001 Jan;69(1):66-71
11180040
Arthritis Res Ther. 2005;7(5):R1046-51
16207320
Pain Physician. 2007 Mar;10(2):357-66
17387357
Am J Surg. 2001 Nov;182(5A Suppl):11S-18S
11755892
J Pain Symptom Manage. 1998 Jan;15(1):1-7
9436336
Intensive Care Med. 2006 Jun;32(6):875-80
16715327
J Physiol Pharmacol. 2004 Mar;55(1 Pt 2):279-88
15082884
J Pain Symptom Manage. 2000 Jul;20(1):19-26
10946165
J Palliat Care. 1991 Winter;7(4):5-8
1783966
Int J Clin Pract. 2007 Jul;61(7):1181-7
17488292
J Clin Pharmacol. 2005 May;45(5):538-46
15831777
J Pain Symptom Manage. 2008 Jan;35(1):103-13
17981003
Expert Opin Investig Drugs. 2006 May;15(5):541-52
16634692